CLINICAL_TRIALS
trial_result
· 2015-12-03
Clinical Trial Update: Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation [Phase 2]
Summary
Phase 2 trial of dasatinib in advanced cancers with DDR2 or B-RAF mutations was terminated; results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Carcinoma, Non-small Cell Lung | Phase 2 | Status: TERMINATED | Results posted: 2015-12-03